In personalized medicine, gene detection technologies and bioinformatics are playing an important role in providing the most appropriate medical care to respective patients. They do this by analyzing detected gene information to help determine individual conditions such as clinical progress and responsiveness to drug therapies.

Toppan Printing, the Institute of Physical and Chemical Research (RIKEN) and RIKEN Venture Capital Co., Ltd., jointly established RIKEN GENESIS in 2007 to accelerate their practical application in real medical settings and widely promote RIKEN's leading-edge research achievements in the field of personalized medicine.

RIKEN GENESIS, which provides lab-assay services as well as products for genetic testing based on cutting-edge gene analysis technologies and bioinformatics, is one of the few Japanese companies that have technologies for and the experience/ know-how in the field of personalized medicine.

Positioning RIKEN GENESIS at the core of its life science business, Toppan Printing has been proactively working on research and development in the domain of genetic testing for personalized medicine. An example of their efforts involved jointly developing a genetic analysis system that enables quick and easy detection of cancer driving somatic gene mutations.

Sysmex has been enhancing its approach to expand their technological portfolio of in-vitro diagnostics for the realization of personalized medicine through the 2013 acquisition of Inostics GmbH, which possesses digital PCR technology2, open innovation with research institutes, universities and medical institutions for biomarker acquisition, and other activities.

Toppan Printing, Sysmex and Riken Genesis have found a common direction in personalized medicine by genetic testing technologies through anticipated technological synergies.

Through this alliance, the companies will aim at expanding platforms for genetic testing technologies and, on a short term basis, global distribution of the Japan-oriented companion diagnostics. This will be achieved by utilizing the pipeline of companion diagnostics projects with pharmaceutical companies in both RIKEN GENESIS and Sysmex.

From the mid-to-long term perspective, the companies will accelerate their approach to personalized medicine by providing high-value biomarkers as new clinical tests to practical medicine through the flexibly to respond to various needs for genetic testing at each stage and supporting a seamless connection between them.

The companies are aiming to establish a place in the global market for Japan-oriented genetic testing technologies by bringing out their comprehensive capabilities in genetic testing as well as driving research and development and business operations.

Company Profile|Print|Alerts

Read the original:
Recent Sysmex News

Comments are closed.